Document is current
Any future updates will be listed below
-
Authors
Han, Mengqi
Xie, Bing
Yu, Yuan
Xu, Dan
Shi, Yuan
Xu, Meng
Wu, Yuming
Zhang, Yujing
Wen, Xiaoyue
Wang, Xin
Zhen, Zifan
Zhang, Xinyu
Sun, Xueqiang
Yuan, Yin
Shang, You
Yuan, Shiying
Hashimoto, Kenji
Zhang, Jiancheng
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82402568)
National Natural Science Foundation of China (82302471)
National Natural Science Foundation of China (82272231)
National Natural Science Foundation of China (82472223)
National Key Research and Development program from Ministry of Science and Technology of the People’s Republic of China (2021YFC2500800)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0529004)
- License Information
-
More Information
Article History
Received: 30 September 2025
Accepted: 4 December 2025
First Online: 18 December 2025
Declarations
:
: Dr. Hashimoto is the inventor of filed patent applications on “The use of R-Ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “R-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “R-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. Hashimoto has also received research support from Otsuka. Other authors declare no conflict of interest.
